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Indiscriminately suppressing total c-Jun N-terminal kinase (JNK) activity is not an appropriate strat-
egy because each JNK appears to have a distinct function in cancer, asthma, diabetes, or Parkinson’s
disease. Herein, we report that 7-(6-N-phenylaminohexyl)amino-2H-anthra[1,9-cd]pyrazol-6-one
(AV-7) inhibited JNK1 activity, but not JNK2 or JNK3. We found that ultraviolet B (UVB) induced
c-Jun phosphorylation and sub-G1 accumulation in JNK2/ murine embryonic ﬁbroblasts, which
contain an abundance of JNK1, but not JNK2. These results demonstrate that AV-7 is an isoform
selective small-molecule inhibitor of JNK1 activity, which might be developed as a therapeutic
against diabetes.
Structured summary:
MINT-7148332: JNK3 (uniprotkb:P53779) phosphorylates (MI:0217) c-JUN (uniprotkb:P05412) by protein
kinase assay (MI:0424)
MINT-7148323: JNK2 (uniprotkb:P45984) phosphorylates (MI:0217) c-JUN (uniprotkb:P05412) by protein
kinase assay (MI:0424)
MINT-7148314: JNK1 (uniprotkb:P45983) phosphorylates (MI:0217) c-JUN (uniprotkb:P05412) by protein
kinase assay (MI:0424)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction TPA in jnk1 (jnk1/) and jnk2 deﬁcient (jnk2/) cells is different,The c-Jun N-terminal kinases (JNKs) are members of the mito-
gen-activated protein (MAP) kinase family [1]. The jnk1 and jnk2
genes are expressed ubiquitously, whereas jnk3 expression is lar-
gely restricted to brain, heart, and testis [2]. The JNKs signal
transduction pathway plays an important role in coordinating
cellular responses including apoptosis [3], proliferation [4], and
neoplastic transformation [5]. Ras-induced transformation re-
quires c-Jun [6] and Ras induces phosphorylation of c-Jun by
JNKs [7]. JNKs are constitutively activated in tumor cell lines
[3] and antisense oligonucleotides targeted against JNKs inhibit
tumor cell growth [8]. In contrast, double knockout of JNK1
and JNK2 caused marked increases in number and growth of
Ras-induced tumor nodules in vivo [9]. We found that JNK2 deﬁ-
cient mice display signiﬁcant suppression of skin papilloma
development induced by 12-O-tetradecanoylphorbal-13-acetate
(TPA) [10]. Importantly, the gene expression pattern induced bychemical Societies. Published by E
mouse embryonic ﬁbroblast;suggesting distinct functions for each kinase [11]. The seemingly
contradictory functions of JNKs were attributed to the idea that
JNKs are activated differentially and probably activate different
substrates based on stimuli or cell type. JNK1, but not JNK2,
was reported to play a role in diabetes [12], and is believed to
be a promising target for diabetes and insulin resistance [13].
Highly selective JNK1 or JNK2 inhibitors will aid greatly in
understanding the precise functions of JNK1 and JNK2. However,
until now, isoform selective inhibitors for JNK1 over JNK2 or
JNK3 activities have not been developed. We report that
7-(6-N-phenylaminohexyl)amino-2H-anthra[1,9-cd]pyrazol-6-one
(AV-7, Fig. 1), which was developed in-house using structure-
based design, shows a selective inhibitory effect against JNK1,
but not JNK2 or JNK3. Functionally, AV-7 suppressed JNK1-med-
iated c-Jun phosphorylation and reversed sub-G1 accumulation.2. Materials and methods
2.1. Reagents and antibodies
AV-7 was synthesized as described in US Patent 61/102,089
[14]. Dulbecco’s modiﬁed Eagle’s medium (DMEM) and fetallsevier B.V. All rights reserved.
Fig. 1. Chemical structure of AV-7.
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(Grand Island, NY). Restriction and modifying enzymes were from
New England BioLabs Inc. (Beverly, MA). The DNA ligation kit
(version 2.0) was obtained from TAKATA Bio Inc. (Otsu, Shiga, Ja-
pan). The antibodies against JNK1 or JNK2 were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA) or from Cell Signaling Technol-
ogy Inc. (Beverly, MA), respectively. Active JNK1, JNK2, and JNK3
were purchased from Upstate Biotechnology Inc. (Charlottesville,
VA) and the 10X kinase buffer for the in vitro kinase assay was
from cell signaling.2.2. Construction of His-c-Jun bacterial expression vector
Human c-Jun cDNA was used for PCR as a template. A fragment
of c-Jun (aa 1-201) was ampliﬁed using primers, hc-Jun-sense:
50-GAC GAC GAC AAG ATG ACT GCA AAG ATG GAA ACG AC-30
and hc-Jun antisense: 50-GAG GAG AAG CCC GGT TTA GGG TTG
CTC GGG AAA GGC CAG-30. The ampliﬁed DNA fragment was puri-
ﬁed from agarose using the QIAEX II DNA extraction kit according
to the manufacturer’s protocol (Qiagen, Valencia, CA). The eluted
DNA was introduced into the pET-46 Ek/LIC His-fusion bacteria
expression vector using the Ek/LIC cloning kit according to the
manufacturer’s instructions (Novagen, Darmstadt, Germany). The
fusion expression vector (pHis-c-Jun-1-201) was conﬁrmed by
restriction enzyme mapping and sequencing.2.3. Puriﬁcation of His-c-Jun-1-201
Brieﬂy, pHis-c-Jun was transformed into BL21 Escherichia coli
and a single colony was cultured overnight in a 37 C shaking incu-
bator. This culture (0.5 ml) was inoculated into 50 ml of bacterial
culture media and incubated until OD600 = 0.6. Protein expression
was induced with IPTG ([ﬁnal] = 0.5 mM) and incubated for 4 h in
a 25 C shaking incubator. The bacteria were harvested by centrifu-
gation, washed twice with ice-cold 1X PBS and His-c-Jun proteins
were puriﬁed using Ni–NTA agarose bead chromatography
(QIAGEN Inc.). Puriﬁed protein was conﬁrmed by Western blotting
with a c-Jun antibody and Coomassie blue R-250 staining.Fig. 2. AV-7 inhibits JNK1, but not JNK2 or JNK3 in vitro. (A–C) Respective in vitro
kinase assays were conducted using 2 lg of a His-c-Jun bacterial-expressed protein,
[c-32P]ATP, AV-7 compound (10 lM), and 20 ng of each commercially active JNK1,
JNK2, or JNK3, respectively. The 32P-labeled phosphorylated c-Jun was visualized by
autoradiography. (D) An in vitro kinase assay was performed with different doses of
AV-7 (2.5–50 lM) and the 32P-labeled phosphorylated c-Jun was visualized by
autoradiography.2.4. In vitro kinase assay
Wildtype His-c-Jun-1-201 protein was used in an in vitro kinase
assay with active JNK1, JNK2, or JNK3 (Upstate). Reactions were
performed at 30 C for 30 min with 20 ng active kinase, 2 lg His-
c-Jun protein, 50 lM unlabeled ATP and 10 lCi [c-32P] ATP.
Reactions were stopped with 6X SDS sample buffer. Samples were
boiled and separated by 12% SDS–PAGE and visualized by
autoradiography.2.5. Cell culture
JNKWT, JNK1/, or JNK2/mouse embryonic ﬁbroblasts (MEFs)
were cultured in DMEM supplemented with 10% heat-inactivated
FBS in a 37 C, 5% CO2 incubator. The cells were maintained by
splitting at 80–90% conﬂuence and media changed every 3 days.
2.6. Western blotting
The proteins were extracted with NP-40 lysis buffer and freez-
ing and thawing. Proteins were resolved by SDS–PAGE, transferred
onto PVDF membranes, hybridized with appropriate antibodies
and then visualized using the ECL detection kit (Amersham Biosci-
ences, Piscataway, NJ).
2.7. MTS Assay
To estimate proliferation, JNKWT, JNK1/, or JNK2/ MEFs
were seeded (1  103) into 96-well plates in 100 ll of 10%
FBS/DMEM and incubated at 37 C, 5% CO2. Proliferation was
measured by adding 20 ll of the CellTiter 96 Aqueous One
Solution (Promega, Madison, WI, USA) and then incubated for 1 h
at 37C, 5% CO2. To stop the reaction, 25 ll of a 10% SDS solution
were added and absorbance measured at 492 and 690 nm.
2.8. Sub-G1 analysis
JNKWT, JNK1/, or JNK2/ MEFs (2  105) were seeded into
60-mm dishes and cultured for 16 h at 37 C, 5% CO2. Cells were
2210 K. Yao et al. / FEBS Letters 583 (2009) 2208–2212treated with different doses of AV-7 for 30 min, stimulated with
ultraviolet B (UVB) (4–8 kJ/m2), and cultured for 24 h. The cells
were harvested by trypsinization, ﬁxed with ice-cold ethanol,
stained with propidium iodide and sub-G1 population analyzed
by ﬂow cytometry.3. Results and discussion
3.1. In vitro kinase assay screening of AV compounds
The phosphorylation of c-Jun by JNKs induces c-Jun transactiva-
tion and transcriptional activity through the formation of a protein
complex with c-Fos or ATF1 (i.e., AP-1 complex). c-Jun/AP-1 en-
hances transcription by binding to the promoter region of many
genes [15]. To analyze the effect of AV-7 on JNKs activity, we con-
ducted in vitro kinase assays using 20 ng each of active JNK1, JNK2,
or JNK3 (commercially available) and 2 lg of bacteria puriﬁed His-
c-Jun-1-201 (as substrate). JNK1 activity was suppressed about
50% by AV-7 (Fig. 2A), with no effect on JNK2 or JNK3 activity
(Fig. 2B and C). Furthermore, we conﬁrmed that JNK1 activity
was inhibited in a dose dependent manner by AV-7 (Fig. 2D).
SP600125 is a non-selective JNKs inhibitor (IC50 0.19 lM) that
binds to the ATP active site [16]. AV-7 was designed to target the
protein-protein interaction between JNK1 and its binding part-
ner(s) rather than the ATP binding site, and at 10 lM speciﬁcally
inhibited JNK1 by about 50% (Fig. 2). These results indicated that
AV-7 is a selective JNK1 inhibitor.
3.2. AV-7 inhibits c-Jun phosphorylation in wildtype and JNK1/
MEFs, but not in JNK2/ MEFs
To evaluate the efﬁcacy of AV-7 ex vivo, we isolated MEFs from
JNK wildtype (JNKWT), JNK1 knockout (JNK1/), and JNK2 knock-Fig. 3. AV-7 inhibits c-Jun phosphorylation ex vivo. (A) JNKs expression in JNKWT, JN
respective 12.5 day-old embryos, cultured and total proteins were extracted. JNK1 and
UVB-induced c-Jun phosphorylation in JNKWT, JNK1/ and JNK2/ MEFs. JNKWT, JNK1/
time indicated (0, 5, 15, 30, 60, 120 min). The proteins were extracted and abundance wa
protein loading.out (JNK2/) embryos (E12.5). JNK1 or JNK2 deﬁciency was con-
ﬁrmed by Western blotting using cell lysates. Results indicated
that JNK2, but not JNK1, was highly abundant in JNK1/ MEFs,
whereas JNK1, but not JNK2, was abundant in JNK2/ MEFs
(Fig. 3A). Next, we examined the UVB responsiveness of c-Jun
phosphorylation in JNKWT, JNK1/ and JNK2/ MEFs (Fig.
3B–D). The results indicated that c-Jun phosphoryaltion was de-
tected at 30 min and increased to 120 min after UVB treatment
in JNKWT and JNK1/ MEFs (Fig. 3B and C). However, phsophory-
lation of c-Jun in JNK2/ MEFs was increased to 60 min and de-
creased at 120 min (Fig. 3D). The phosphorylation of JNK was
variable in different cell types. We found that phosphorylation of
JNK1/2 in wildtype cells was detected at 30 min and continuously
increased to 120 min after UVB stimulation (Fig. 3B). JNK2 phos-
phorylation was detected at 15 min and peaked at 30 min in
JNK1/ MEFs (Fig. 3C). JNK1 phosphorylation occurred faster and
was detected at 5 min and constantly increased to 120 min in
JNK2/ MEFs (Fig. 3D). We examined that inhibitory effect of
AV-7 on c-Jun phosphorylation in the three cell types over time
(Fig. 4A). The results indicated that UVB-induced c-Jun phosphory-
lation was slightly decreased in JNKWT MEFs by A-7 treatment
(Fig. 4A, top panel). However, phosphorylation of c-Jun was not
affected in JNK1/ MEFs (Fig. 4A, middle panel). Importantly,
c-Jun phosphorylation was dramatically decreased in JNK2/
MEFs, which express high levels of JNK1 (Fig. 4A, bottom panel).
We used 30 min after UVB treatment as the optimal time point
in further experiments to examine the inhibitory effect of AV-7
on c-Jun phosphorylation mainly because c-Jun phosphorylation
and JNKs phosphorylation were detected in all three MEF types
at 30 min after UVB irradiation and longer time intervals (60 or
120) allow other signaling to be activated and affect c-Jun phos-
phorylation. As expected, SP600125 is a more potent of JNKs but
without selectivity (Fig. 4A). Our previous studies indicated that
JNK1 and JNK2 have opposite roles in the development of mouseK1/, and JNK2/ MEFs. JNKWT, JNK1/, and JNK2/ MEFs were isolated from
JNK2 proteins were visualized by Western blotting with speciﬁc antibodies. (B–D)
or JNK2/ MEFs were cultured, treated with UVB (4 kJ/m2) and harvested in at the
s analyzed by Western blot with speciﬁc antibodies. b-Actin was used to verify equal
Fig. 4. AV-7 inhibits JNK1-mediated, but not JNK2-mediated, c-Jun phosphorylation. (A) AV-7 inhibits c-Jun phosphorylation in JNK2/ MEFs. JNKWT, JNK1/ and JNK2/
MEFs were treated 10 lM AV-7 or SP600125 and then stimulated with UVB (4 kJ/m2). The cells were harvested at the indicated time and protein levels of c-Jun and JNKs were
visualized by Western blot. b-Actin was used to verify equal protein loading. (B–D) The effect of AV-7 on UVB-induced c-Jun phosphorylation in JNKWT, JNK1/, and JNK2/
MEFs. The cells were cultured, treated with AV-7 for 30 min, and then treated with UVB (4 kJ/m2) and harvested 30 min later. The proteins were extracted and abundance was
analyzed by Western blot with speciﬁc antibodies as indicated. b-Actin was used to verify equal protein loading.
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of AV-7 in more detail, each respective MEF type was treated with
AV-7 (10 lM) for 30 min followed by UVB (4 kJ/m2) in the same
medium containing AV-7. The cells were harvested 30 min after
UVB treatment and the phosphorylation of JNKs and c-Jun was
determined. UV-induced JNKs phosphorylation was detected in
UV-treated JNKWT, JNK1/, and JNK2/ MEFs (Fig. 4B–D). As
expected, c-Jun phosphorylation was only slightly or not affected
by AV-7 treatment in JNKWT or JNK1/ MEFs, respectively
(Fig. 4B and C, respectively). Importantly, the increased c-Jun phos-
phorylation induced by UVB stimulation was suppressed by treat-
ment with AV-7 in a dose dependant manner in JNK2/ MEFs,
which only express JNK1 (Fig. 4D). However, why c-Jun phosphor-
ylation was increased by AV-7 treatment in JNK1/ MEFs is un-
clear and will be studied in the future. These results
demonstrated that AV-7 speciﬁcally inhibits JNK1-mediated c-Jun
phosphorylation in JNK2/ MEFs.3.3. AV-7 suppresses UVB-induced accumulation of sub-G1 population
in JNK2/ cells
Our previous studies [16] strongly indicate that JNK1 deﬁciency
might enhance cell proliferation, whereas JNK2 deﬁciency could
have the opposite effect. To conﬁrm this idea, we analyzed
proliferation by MTS assay and results indicated that JNKWT and
JNK1/ MEFs did not differ in proliferation rate over 96 h
(Fig. 5A). However, JNK2 deﬁciency inhibited proliferation
(Fig. 5A). Previous studies by other groups have shown that
JNK2/ MEFs exhibit a higher percentage of basal apoptosis [17]
and enhanced DNA fragmentation induced by UV treatment [18].
Our ﬁndings agree well with our previous results indicating that
JNK1/ enhanced skin tumor formation [16], whereas JNK2/
suppressed skin tumor development [10]. These data also sug-
gested that JNK2 deﬁciency (i.e., high JNK1 expression) might cause
an increase in inducible sub-G1 population and that AV-7 might
Fig. 5. AV-7 inhibits UVB-induced and JNK1-mediated accumulation of cells in sub-
G1 phase. (A) Proliferation of JNKWT, JNK1/ and JNK2/MEFs. JNKWT, JNK1/ and
JNK2/ MEFs (1000 cells/well) were seeded into 96-well plates and proliferation
was measured by MTS assay after 2 h (for 0 time point) and then every 24 h. (B)
UVB induces sub-G1 population. JNKWT, JNK1/ and JNK2/ MEFs (2  105) were
seeded into 60-mm culture dishes and treated with UVB or AV-7/UVB as indicated.
The cells were cultured for 24 h at 37 C in a 5% CO2 incubator and harvested, ﬁxed,
and sub-G1 population analyzed by ﬂow cytometry. Data are represented as
mean ± S.D. of values from triplicate experiments and signiﬁcant differences were
evaluated using the Student’s t-test (*p < 0.05; **p < 0.01).
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in JNK2/ MEFs. This suggestion is supported by our recent study
indicating that UVA treatment of JNK2/MEFs enhanced apoptosis
comparedwith JNKWT or JNK1/MEFs [19]. Other studies have also
shown that JNK2 knockdown-mediated growth inhibition by JNK2
antisense corresponds with substantial apoptosis [20], and down-
regulation of JNK1 expression inhibits apoptosis [21]. We treated
cells with UVB (8 kJ/m2) and analyzed sub-G1 population in JNKWT,
JNK1/ and JNK2/MEFs. JNKwildtype cells express high levels of
both JNK1 and JNK2 (see Fig. 3A) and thus one might not expect a
speciﬁc JNK1 or JNK2 inhibitor to affect these cells to a large degree
because of their potentially similar function in apoptosis. JNK1
knockout cells only express high levels of JNK2 (Fig. 3A) and there-
fore an inhibitor that speciﬁcally suppresses only JNK1 activation
would have no effect as is shown in Fig. 5B. JNK2 knockout cells ex-
press only JNK1 (Fig. 3A) and therefore a speciﬁc JNK1 inhibitor
should have a greater effect only in these cells as is illustrated in
Fig. 5B. Thus as a model system, JNK1 and JNK2 knockout cells
can be used to show speciﬁcity of a JNK1 isoform inhibitor.
These results demonstrate that AV-7 is an isoform selective
JNK1 inhibitor. In humans, JNKs play a key role in obesity-induced
type 2 diabetes mellitus and the absence of JNK1 results in de-
creased adiposity, signiﬁcantly improved insulin sensitivity andan enhanced insulin receptor signaling capacity in mouse obesity
models [12]. Therefore, we suggest that because of JNK1’s critical
role in diabetes [12], AV-7 might have therapeutic potential
against this devastating disease.Acknowledgments
Thiswork is supported by a grant from theMinnesota Partnership
for Biotechnology and Medical Genomics (L9046001101), The Hor-
mel Foundation, theMayo Foundation forMedical Education and Re-
search, and the University of Minnesota Supercomputing Institute.References
[1] Weston, C.R. and Davis, R.J. (2002) The JNK signal transduction pathway. Curr.
Opin. Genet. Dev. 12, 14–21.
[2] Davis, R.J. (2000) Signal transduction by the JNK group of MAP kinases. Cell
103, 239–252.
[3] Ip, Y.T. and Davis, R.J. (1998) Signal transduction by the c-Jun N-terminal
kinase (JNK) – from inﬂammation to development. Curr. Opin. Cell Biol. 10,
205–219.
[4] Bost, F., McKay, R., Dean, N. and Mercola, D. (1997) The JUN kinase/stress-
activated protein kinase pathway is required for epidermal growth factor
stimulation of growth of human A549 lung carcinoma cells. J. Biol. Chem. 272,
33422–33429.
[5] Rodrigues, G.A., Park, M. and Schlessinger, J. (1997) Activation of the JNK
pathway is essential for transformation by the Met oncogene. Embo J. 16,
2634–2645.
[6] Johnson, R., Spiegelman, B., Hanahan, D. and Wisdom, R. (1996) Cellular
transformation and malignancy induced by ras require c-jun. Mol. Cell Biol. 16,
4504–4511.
[7] Smeal, T., Binetruy, B., Mercola, D.A., Birrer, M. and Karin, M. (1991) Oncogenic
and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun
on serines 63 and 73. Nature 354, 494–496.
[8] Bost, F., McKay, R., Bost, M., Potapova, O., Dean, N.M. and Mercola, D. (1999)
The Jun kinase 2 isoform is preferentially required for epidermal growth
factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell
Biol. 19, 1938–1949.
[9] Kennedy, N.J., Sluss, H.K., Jones, S.N., Bar-Sagi, D., Flavell, R.A. and Davis, R.J.
(2003) Suppression of Ras-stimulated transformation by the JNK signal
transduction pathway. Gene Dev. 17, 629–637.
[10] Chen, N., Nomura, M., She, Q.B., Ma, W.Y., Bode, A.M., Wang, L., Flavell, R.A. and
Dong, Z. (2001) Suppression of skin tumorigenesis in c-Jun NH(2)-terminal
kinase-2-deﬁcient mice. Cancer Res. 61, 3908–3912.
[11] Chen, N., She, Q.B., Bode, A.M. and Dong, Z. (2002) Differential gene expression
proﬁles of Jnk1- and Jnk2-deﬁcient murine ﬁbroblast cells. Cancer Res. 62,
1300–1304.
[12] Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin,
M. and Hotamisligil, G.S. (2002) A central role for JNK in obesity and insulin
resistance. Nature 420, 333–336.
[13] Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M. and Hotamisligil, G.S.
(2006) Functional in vivo interactions between JNK1 and JNK2 isoforms in
obesity and insulin resistance. Proc Natl. Acad. Sci. USA 103, 10741–
10746.
[14] Pang, Y.-P., Vummenthala, A., Park, J.G., Wang, S.-H., Dong, Z., Bode, A.M. and
Cho, Y.-Y. (2008). Selective inhibitors of c-Jun N-terminal Kinases (application,
U.S.P. p., ed. ^ends), US.
[15] Karin, M., Liu, Z. and Zandi, E. (1997) AP-1 function and regulation. Curr. Opin.
Cell Biol. 9, 240–246.
[16] She, Q.B., Chen, N., Bode, A.M., Flavell, R.A. and Dong, Z. (2002) Deﬁciency of c-
Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by
12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62, 1343–1348.
[17] Sabapathy, K., Hochedlinger, K., Nam, S.Y., Bauer, A., Karin, M. andWagner, E.F.
(2004) Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-
dependent cell proliferation. Mol. Cell 15, 713–725.
[18] Tournier, C. et al. (2000) Requirement of JNK for stress-induced activation of
the cytochrome c-mediated death pathway. Science 288, 870–874.
[19] Choi, H.S., Bode, A.M., Shim, J.H., Lee, S.Y. and Dong, Z. (2009) C-Jun N-terminal
kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. Mol. Cell
Biol. 29, 2168–2180.
[20] Potapova, O., Gorospe, M., Dougherty, R.H., Dean, N.M., Gaarde, W.A. and
Holbrook, N.J. (2000) Inhibition of c-Jun N-terminal kinase 2 expression
suppresses growth and induces apoptosis of human tumor cells in a p53-
dependent manner. Mol. Cell Biol. 20, 1713–1722.
[21] Cerezo, A., Martinez, A.C., Gonzalez, A., Gomez, J. and Rebollo, A. (1999) IL-2
deprivation triggers apoptosis which is mediated by c-Jun N-terminal kinase 1
activation and prevented by Bcl-2. Cell Death Differ. 6, 87–94.
